104.21
-0.3(-0.29%)
Currency In USD
| Previous Close | 104.51 |
| Open | 104.32 |
| Day High | 106.38 |
| Day Low | 104.05 |
| 52-Week High | 112.64 |
| 52-Week Low | 7.58 |
| Volume | 434,090 |
| Average Volume | 1.05M |
| Market Cap | 4.82B |
| PE | -28.32 |
| EPS | -3.68 |
| Moving Average 50 Days | 95.75 |
| Moving Average 200 Days | 46.32 |
| Change | -0.3 |
If you invested $1000 in Celcuity Inc. (CELC) since IPO date, it would be worth $7,292.51 as of January 14, 2026 at a share price of $104.21. Whereas If you bought $1000 worth of Celcuity Inc. (CELC) shares 5 years ago, it would be worth $8,868.94 as of January 14, 2026 at a share price of $104.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 11, 2025 7:35 PM GMT
For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and 10.0 months with gedatolisib + fulvest
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Nov 26, 2025 9:05 PM GMT
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at t
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2025 12:05 PM GMT
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Healthcare Con